Kidney cancer: open trials in Germany

19 open trials have a site in Germany. Registry data; only the trial team decides who can take part.

NCT03374267
Registry Platform Urologic Cancer
Research · iOMEDICO AG
Multiple sites, Germany, Multiple Locations
Registry updated 2026-11-05
NCT07011719
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Trial Treatment · Phase 3 · Arcus Biosciences, Inc.
Charite Universitaetsmedizin Berlin KöR, Berlin · HELIOS Klinikum Berlin Buch GmbH, Berlin · Technische Universitaet Dresden, Dresden · Universitaetsklinikum Essen (AoR), Essen · Krankenhaus Nordwest GmbH, Frankfurt am Main · Medical Center- University of Freiburg, Freiburg im Breisgau · Universitaetsklinikum Halle (Saale) AöR, Halle Saale · Medizinische Hochschule Hannover, Hanover · Universitaetsklinikum Heidelberg AöR, Heidelberg · Universitaet Leipzig, Leipzig · Universitaetsklinikum Schleswig-Holstein AöR, Luebeck · Philipps-Universitaet Marburg, Marburg · Rostock University Medical Center, Rostock · Universitaetsklinikum Ulm AoR, Ulm
Registry updated 2026-11-02
NCT07888322
Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
Research · Aristotle University Of Thessaloniki
Department of Neuroradiology, Charite, Berlin · Klinikum rechts der Isar, TUM, München
Registry updated 2026-11-02
NCT07489495
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Universitaetsklinikum Augsburg, Augsburg · Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsklinikum Heidelberg AöR, Heidelberg · Universitaetsklinikum Jena KöR, Jena · Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), Munich
Registry updated 2026-10-29
NCT07293351
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Trial Treatment · Phase 1/2 · Bristol-Myers Squibb
University Medical Center Hamburg-Eppendorf, Hamburg · St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr, Herne · Universitaetsklinikum Jena KöR, Jena · Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), Munich
Registry updated 2026-10-23
NCT06026410
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Trial Treatment · Phase 1 · Kura Oncology, Inc.
Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsklinikum Ulm AoR, Ulm · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-10-14
NCT07227415
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Trial Treatment · Phase 1/2 · Pfizer
Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR, Dresden · Universitaetsklinikum Essen (AoR), Essen · Universitaetsklinikum Heidelberg AöR, Heidelberg
Registry updated 2026-10-08
2025-524160-38-00
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Universitaetsklinikum Magdeburg AöR, Magdeburg
Registry updated 2026-10-01
NCT05176483
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Trial Treatment · Phase 1 · Exelixis
Universitaetsklinikum Essen (AoR), Essen · Universitaetsklinikum Heidelberg AöR, Heidelberg · Marien Hospital Herne Universitatsklinikum Der Ruhr-Universitat Bochum, Herne · Universitaetsklinikum Jena KöR, Jena · Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR, Nuertingen · Universitaetsklinikum Tuebingen AöR, Tuebingen
Registry updated 2026-10-01
NCT07848295
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Trial Treatment · Phase 1 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Essen · Jena
Registry updated 2026-09-30
2023-503317-29-00
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Trial Treatment · Phase 3 · Institut Gustave Roussy
Universitaetsklinikum Duesseldorf AöR, Duesseldorf · Universitaetsklinikum Essen (AoR), Essen · Goethe University Frankfurt, Frankfurt Am Main · Medizinische Hochschule Hannover, Hanover · Heidelberg University, Heidelberg · Marien Hospital Herne Universitatsklinikum Der Ruhr-Universitat Bochum, Herne · Ludwig-Maximilians-Universitaet Muenchen, Munich · Universitätsklinikum Münster, Münster · Klinikum Der Landeshauptstadt Stuttgart gKAöR, Stuttgart · Universitätsklinikum Tübingen, Tübingen
Registry updated 2026-09-28
NCT05059444
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Research · Guardant Health, Inc.
Asklepios Klinik Altona, Hamburg · SLK-Kliniken Heilbronn GmbH, Heilbronn · Ludwig Maximilian University Munich, Munich
Registry updated 2026-09-14
NCT07803315
Hyperspectral Imaging in Robot-Assisted Partial Nephrectomy
Research · University of Leipzig
University Hospital Leipzig, Leipzig
Registry updated 2026-09-03
NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Trial Treatment · Phase 1/2 · Bristol-Myers Squibb
Universitaetsklinikum Carl Gustav Carus Dresden-University Cancer Center Early Clinical Trial Unit, Dresden · Universitaetsklinikum - Essen, Essen · Universitätsklinikum Frankfurt, Frankfurt · Ulm · Universitaetsklinikum Wuerzburg, Würzburg
Registry updated 2026-08-17
NCT07227402
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Charite Universitaetsmedizin Berlin KöR, Berlin · Technische Universitaet Dresden, Dresden · HELIOS Klinikum Erfurt GmbH, Erfurt · Universitaetsmedizin Goettingen, Goettingen · University Medical Center Hamburg-Eppendorf, Hamburg · St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr, Herne · Universitaetsklinikum Jena KöR, Jena · Universitaetsklinikum Muenster AöR, Muenster · Studienpraxis Urologie Susan Feyerabend MD Tilman Todenhoefer MD PhD GbR, Nuertingen · Rostock University Medical Center, Rostock · HELIOS Kliniken Schwerin GmbH, Schwerin · Klinikum Der Landeshauptstadt Stuttgart gKAöR, Stuttgart · Universitaetsklinikum Tuebingen AöR, Tuebingen
Registry updated 2026-08-03
NCT06413680
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Trial Treatment · Phase 1/2 · Regeneron Pharmaceuticals
Universitaetsklinikum Bonn AöR, Bonn · Universitaetsklinikum Erlangen AöR, Erlangen · Universitaetsklinikum Essen (AoR), Essen · University Medical Center Hamburg-Eppendorf, Hamburg · SLK-Kliniken Heilbronn GmbH, Heilbronn
Registry updated 2026-04-28
NCT07246759
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
Research · OncoHost Ltd.
Heidelberg University Hospital, Heidelberg
Registry updated 2025-11-24
NCT04892849
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
Research · University of Erlangen-Nürnberg Medical School
Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen
Registry updated 2025-09-17
NCT04498767
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
Trial Treatment · European Organisation for Research and Treatment of Cancer - EORTC
Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center, Hamburg
Registry updated 2024-08-26

All Kidney cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error